Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.

Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10.

PMID:
20452659
2.

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.

J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8.

3.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS.

J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9.

4.

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA.

Gynecol Oncol. 2006 Jan;100(1):83-8. Epub 2005 Aug 31.

PMID:
16137751
5.

Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.

Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, Royer R, McLaughlin J, Karlan B, Narod SA.

Gynecol Oncol. 2010 Sep;118(3):299-302. doi: 10.1016/j.ygyno.2010.05.011. Epub 2010 Jun 8.

PMID:
20570322
6.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

7.

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY.

Obstet Gynecol. 2005 Dec;106(6):1327-34.

PMID:
16319259
8.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

9.

Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.

Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H.

Mod Pathol. 2009 Sep;22(9):1133-8. doi: 10.1038/modpathol.2009.89. Epub 2009 Jun 19.

10.

Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P.

J Natl Cancer Inst. 2003 Jul 16;95(14):1072-8.

11.

Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group, Garber J, Osborne M, Fishman D, McLennan J, McKinnon W, Merajver S, Olsson H, Provencher D, Pasche B, Evans G, Meschino WS, Lemire E, Chudley A, Rayson D, Bellati C.

Breast Cancer Res Treat. 2007 Oct;105(2):221-8. Epub 2007 Jan 24.

PMID:
17245541
12.

Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.

Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA.

Gynecol Oncol. 2001 Feb;80(2):176-80.

PMID:
11161856
13.

Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.

Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3170-8. doi: 10.1158/1055-9965.EPI-08-0396.

14.

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J.

Breast Cancer Res Treat. 2010 Jan;119(1):221-32. doi: 10.1007/s10549-009-0394-1. Epub 2009 Apr 16.

PMID:
19370414
15.

Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Struewing JP, Tucker MA, Wacholder S; National Israel Ovarian Cancer Study Group.

N Engl J Med. 2001 Jul 26;345(4):235-40.

16.

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P, Narod SA.

Breast Cancer Res. 2005;7(5):R833-43. Epub 2005 Aug 19.

17.

Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.

Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.

Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.

PMID:
18830124
18.

A genetic epidemiological study of carcinoma of the fallopian tube.

Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, Narod SA.

Gynecol Oncol. 2001 Mar;80(3):341-5.

PMID:
11263928
19.

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.

Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN.

BMC Cancer. 2008 Apr 10;8:96. doi: 10.1186/1471-2407-8-96.

20.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

Items per page

Supplemental Content

Write to the Help Desk